Pancreatic adenocarcinoma induces bone marrow mobilization of myeloid-derived suppressor cells which promote primary tumor growth. - Wikidata - awgldk - TriplyDB

Pancreatic adenocarcinoma induces bone marrow mobilization of myeloid-derived suppressor cells which promote primary tumor growth.

Pancreatic adenocarcinoma induces bone marrow mobilization of myeloid-derived suppressor cells which promote primary tumor growth.

http://www.wikidata.org/entity/Q36971755

about

Genetics and biology of pancreatic ductal adenocarcinoma Myeloid-Derived Suppressor Cells: Critical Cells Driving Immune Suppression in the Tumor Microenvironment Evolution and dynamics of pancreatic cancer progression The impact of the myeloid response to radiation therapy Myeloid-derived suppressor cells in cancer: therapeutic, predictive, and prognostic implications Immune suppression by neutrophils and granulocytic myeloid-derived suppressor cells: similarities and differences Myeloid derived suppressor cells-An overview of combat strategies to increase immunotherapy efficacy The Nature of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment A phase I study of IMP321 and gemcitabine as the front-line therapy in patients with advanced pancreatic adenocarcinoma Myeloid-derived suppressor cells in the development of lung cancer.Pancreatic ductal adenocarcinoma contains an effector and regulatory immune cell infiltrate that is altered by multimodal neoadjuvant treatment.32-Phosphorus selectively delivered by listeria to pancreatic cancer demonstrates a strong therapeutic effect.Myeloid derived suppressor cells - a new therapeutic target in the treatment of cancer.The receptor for advanced glycation end products promotes pancreatic carcinogenesis and accumulation of myeloid-derived suppressor cells.Paradoxical myeloid-derived suppressor cell reduction in the bone marrow of SIV chronically infected macaques.Stromal reengineering to treat pancreas cancer Chemotherapy and tumor microenvironment of pancreatic cancer.Tumor-induced myeloid deviation: when myeloid-derived suppressor cells meet tumor-associated macrophages Complex role for the immune system in initiation and progression of pancreatic cancer.Myeloid-derived suppressor cells are associated with disease progression and decreased overall survival in advanced-stage melanoma patients Anti-Bv8 antibody and metronomic gemcitabine improve pancreatic adenocarcinoma treatment outcome following weekly gemcitabine therapy.Identification of myeloid derived suppressor cells in the peripheral blood of tumor bearing dogs.Pancreatic tumors and immature immunosuppressive myeloid cells in blood and spleen: role of inhibitory co-stimulatory molecules PDL1 and CTLA4. An in vivo and in vitro study.Molecular pathways: myeloid complicity in cancer.Targeted depletion of an MDSC subset unmasks pancreatic ductal adenocarcinoma to adaptive immunity.Complexity and challenges in defining myeloid-derived suppressor cells Unbiased analysis of pancreatic cancer radiation resistance reveals cholesterol biosynthesis as a novel target for radiosensitisation Characterization of myeloid leukocytes and soluble mediators in pancreatic cancer: importance of myeloid-derived suppressor cells.Patients with pancreatic adenocarcinoma exhibit elevated levels of myeloid-derived suppressor cells upon progression of disease Attenuated Toxoplasma gondii Stimulates Immunity to Pancreatic Cancer by Manipulation of Myeloid Cell Populations.Trial watch: Prognostic and predictive value of the immune infiltrate in cancer Bisphosphonates as potential adjuvants for patients with cancers of the digestive system.Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanoma.Tumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans Dickkopf-related protein 1 (Dkk1) regulates the accumulation and function of myeloid derived suppressor cells in cancer.Inflammatory monocyte mobilization decreases patient survival in pancreatic cancer: a role for targeting the CCL2/CCR2 axis.A Study of Zoledronic Acid as Neo-Adjuvant, Perioperative Therapy in Patients with Resectable Pancreatic Ductal Adenocarcinoma.Down-regulation of PLCγ2-β-catenin pathway promotes activation and expansion of myeloid-derived suppressor cells in cancer.Targeting tumor-infiltrating macrophages to combat cancer.Role of immune cells in pancreatic cancer from bench to clinical application: An updated review

P2860

Q26765438-8ED21014-E670-46C5-8334-BDE1E25C805B Q26799126-B6BEC7A1-64DC-485D-9298-33D4E43F1BD0 Q26849671-C7A3271B-0EBD-4AEF-868A-EFF77EFC7DC2 Q26851643-23F39BE5-B461-43E9-A54F-5CBF9C6EC3AE Q27014189-2B1A5747-2FD3-4891-9F9E-6C4FAC61688F Q27027064-446D17D7-5110-480E-9D9B-40CBE648A883 Q28082461-080E29E3-581F-487C-BC08-8568A37636EA Q28388630-F8343564-76AB-4D69-9FD4-3FE7FBC85143 Q30412791-ACB5777A-FF66-4D0D-8016-EDB75B6AE702 Q33555717-DEFF8CD0-F060-492F-B597-37AC54A5462A Q33560501-8F5639C0-071F-4C86-B334-A586FB2FA70F Q33591328-070D86F2-EE24-46A4-A867-797E3DC17AA4 Q33606107-63FB2E4D-841D-4BC2-A6BD-757F814E8C23 Q33709243-7048E4B1-DE1A-40A2-A37D-7C935358773F Q33739465-C22B48E7-B45C-4979-9DE0-180344870910 Q33827708-E166AB7D-F8F9-4069-A124-0F9343EBA216 Q33876637-D4E1560C-ACBB-4C4E-9C51-3D0A483D30CA Q34044797-3511D896-2444-4ADD-BB50-46D408756B54 Q34093784-38DC037C-6B05-47B1-A56D-438D89A16DEC Q34250873-878300E0-E921-4D31-9EDF-B502BF0FEA9C Q34346752-1E5E66C8-9F62-456A-89DB-2380F9A4BD63 Q34461732-BE9F3FE2-4C41-4D72-8235-2D6E2C9CE70F Q34566554-A816BDB2-1745-4865-8ACB-CBF2AC9F4FDA Q34725969-06135833-348B-4DAA-829F-EE6D4A157998 Q35121535-C051A9F3-6B9E-4690-8507-891D21B1E79D Q35509317-F6A01228-C551-4EE5-9EAC-A72A4BB35AF9 Q35678372-CF76D541-48DD-40C0-9FF2-E2E5390DFB76 Q35799021-BC5CDF4D-D920-4B85-AF61-3E24AEA9EAF5 Q35857561-E5BB6B88-EAC2-4AB9-A547-E2F1C88A577D Q35920573-9E8A9339-3E20-474E-A039-BB41A3ADB483 Q36456483-3A9D79EF-3126-4D85-A78E-4D9C8EEA70F5 Q36471673-1E43FCFA-DAF3-41AA-AA66-55715C44E40B Q36612452-C284C0A6-242D-4B2C-90D0-9D4FD00B2049 Q36761567-03D1418D-19BD-45EE-9B3E-C5BFD0AF9123 Q36863121-7E5B33B1-04D0-408B-9F8B-DA9EEEE0B85C Q36980064-22E04B1A-47A6-4E4B-AA4F-8BE3B7F7DFC0 Q37206372-73F99EA4-767E-4100-A84B-60CC22D17E08 Q37246466-2347EFF0-D983-428F-BB9B-41B293AF4E9A Q37401717-5BB9B4BC-D6ED-4A9E-9808-621A390ED1AC Q37606102-E436A041-BDA0-4764-AE7F-6F3D3E06FC1C

P2860

Pancreatic adenocarcinoma induces bone marrow mobilization of myeloid-derived suppressor cells which promote primary tumor growth.

http://www.wikidata.org/entity/Q36971755

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Pancreatic adenocarcinoma indu ...... promote primary tumor growth.

@en

type

label

Pancreatic adenocarcinoma indu ...... promote primary tumor growth.

@en

prefLabel

Pancreatic adenocarcinoma indu ...... promote primary tumor growth.

@en

P1433

Q36971755-2543E176-D019-41D1-B6B1-6584279DFF47

P1476

Q36971755-F92157A6-6EA3-4D99-B341-F3F95FE60CEC

P2093

Q36971755-027A195D-0137-44A0-BF63-5CF11FE41E04

Q36971755-29E5F6DA-C13B-49F0-AA71-3FBF460D3C31

Q36971755-3AFE5702-48CF-46BF-954E-AAB8CF23FB0A

Q36971755-5295D854-A5EC-452F-B7D1-50489CA83308

Q36971755-5574F760-6D35-4057-A383-5977E7E7E433

Q36971755-935C8605-3BC9-472D-B215-E03B74765590

Q36971755-9AC8BECF-BCC7-4328-9477-79012B3752B6

Q36971755-E786E114-2EA4-4473-B60C-74EF73DA1EEB

P2860

Q36971755-00C8804F-D5ED-439A-B9D4-77A942D737E8

Q36971755-0BE80EA9-EB2B-4748-87A4-5C1466A34451

Q36971755-0D1857B2-CBBA-4DA5-A140-CA410240CDA0

Q36971755-124BC8C7-237F-4CE6-8252-C7CE5C0E9F74

Q36971755-18FCAEB6-FDDD-4BD4-95FE-5D768ACC6494

Q36971755-1CCBD534-C980-4C5F-9AF6-27CBA6CF9DD6

Q36971755-23B8E17B-DB22-4C35-A2A6-9869C5C11909

Q36971755-257EC1E9-A29C-4594-8E7B-EFEA380B2F79

Q36971755-284EED8A-2268-4928-BF8F-CABE60769B78

Q36971755-2BC438A7-0F33-49A4-A4A8-054188FD43EF

P2888

Q36971755-1B3AB7D5-E051-4F52-8A18-EF1458E3FDD1

P304

Q36971755-DBA0FD7D-90E1-4055-A2E5-88C2A382D8A5

P31

Q36971755-520DE6DF-F6B2-446D-9BD3-E8CFF56843FC

P356

Q36971755-125FC2F9-235E-4B8D-A50B-F6795FE73158

P433

Q36971755-E88A86DF-926C-4C4A-9A78-FB29133A9948

P478

Q36971755-F9867E3F-5E2E-4263-A3DD-A14EE30060E7

P50

Q36971755-8BCB0B75-288A-4028-9C1E-DD3A1D145C13

P577

Q36971755-1ECE4D02-C6E4-433E-9E75-F258B8CC0D02

P5875

Q36971755-050A8893-C245-44EE-A7D6-D0AB09A7E431

P698

Q36971755-4C23CBAF-0F64-4CF7-B204-5BE9CF068246

P921

Q36971755-9CED870A-0B43-407F-80D5-1838A56E122A

P932

Q36971755-31D7132E-8305-44C8-A9AF-22EA0F1D3999

P356

S00262-011-1178-0

P1433

Cancer Immunology, Immunotherapy

P1476

Pancreatic adenocarcinoma indu ...... h promote primary tumor growth

@en

P2093

Brian A Belt

http://www.w3.org/2001/XMLSchema#string

Chyi-Song Hsieh

http://www.w3.org/2001/XMLSchema#string

David C Linehan

http://www.w3.org/2001/XMLSchema#string

Hyang-Mi Lee

http://www.w3.org/2001/XMLSchema#string

John Herndon

http://www.w3.org/2001/XMLSchema#string

Matthew R Porembka

http://www.w3.org/2001/XMLSchema#string

Peter Goedegebuure

http://www.w3.org/2001/XMLSchema#string

William E Gillanders

http://www.w3.org/2001/XMLSchema#string

P2860

Cancer statistics, 2010

Myeloid-derived suppressor cells as regulators of the immune system

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

Subsets of myeloid-derived suppressor cells in tumor-bearing mice

Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

Myeloid-derived suppressor cells down-regulate L-selectin expression on CD4+ and CD8+ T cells.

Myeloid-derived suppressor cells inhibit T-cell activation by depleting cystine and cysteine.

Mechanism of T cell tolerance induced by myeloid-derived suppressor cells.

Mechanism regulating reactive oxygen species in tumor-induced myeloid-derived suppressor cells.

Anti-inflammatory triterpenoid blocks immune suppressive function of MDSCs and improves immune response in cancer.

P2888

s00262-011-1178-0

P304

1373-1385

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00262-011-1178-0

http://www.w3.org/2001/XMLSchema#string

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

61

http://www.w3.org/2001/XMLSchema#string

P50

Jonathan B. Mitchem

P577

2012-01-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51979146

http://www.w3.org/2001/XMLSchema#string

P698

22215137

http://www.w3.org/2001/XMLSchema#string

P921

P932

3697836

http://www.w3.org/2001/XMLSchema#string